Novo Nordisk A/S
Behind Anthropic’s stunning growth is a sibling team that may hold the key to generative AI
SAN FRANCISCO — Daniela Amodei has an energy that’s hard to place — warm, unhurried, immediately present. She swept into a sunlit room on the ground floor of Anthropic’s headquarters in December, sat down, and immediately apologized for her mug. “Is my, like, gigantic novelty mug going to be distracting if I have it?” she […]
Read More
2026 is the year of obesity pills. Here’s how they could reshape the GLP-1 market
The booming GLP-1 space was built on weekly injections. In 2026, new obesity pills will push the market into its next chapter. Patients are already getting their hands on the first GLP-1 pill for obesity from Danish drugmaker Novo Nordisk — a once-daily drug that shares the same brand name as its popular injection Wegovy. […]
Read More
Healthy Returns: What to expect from pharma at the JPM conference
Heidi Overton, Novo Nordisk CEO Maziar Mike Doustdar, Eli Lilly CEO David A. Ricks, and U.S. Secretary of Commerce Howard Lutnick listen while U.S. President Donald Trump announces a deal with Eli Lilly and Novo Nordisk on to reduce the prices of GLP-1 weight‑loss drugs during an event in the Oval Office at the White […]
Read More
Amazon Pharmacy starts offering Novo Nordisk’s Wegovy weight-loss pill
Close-up of a hand holding a cellphone displaying the Amazon Pharmacy system, Lafayette, California, September 15, 2021. Smith Collection | Gado | Getty Images Amazon announced Friday it now offers Novo Nordisk‘s Wegovy weight-loss pill through its digital pharmacy. Novo Nordisk began rolling out an oral version of its injectable obesity drug Wegovy in the […]
Read More
A little-known biotech stock has become a prime takeover target after surging nearly 1,700% last year
Europe’s best-performing blue-chip stock in 2025 is widely expected to be bought by a larger peer, in a deal analysts say could be worth as much as $23 billion. Abivax, the French clinical-stage biotech company developing a treatment for ulcerative colitis and Crohn’s disease, saw shares rocket 1,681% last year, far outpacing the Stoxx 600 […]
Read More
Big Pharma race to snap up biotech assets as $170 billion patent cliff looms
Two employees in pharmaceutical industry wearing protective gloves, mask, cap and white suit seen standing by the machine that is the part of the medicaments production during the working hours in a pharmaceutical manufacturing. Extreme-photographer | E+ | Getty Images A multitude of factors are coming together to bring a big burst in biotech M&A. […]
Read More
First GLP-1 pill for obesity from Novo Nordisk launches in the U.S.
The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, on the outskirts of Copenhagen, Nov. 24, 2025. Tom Little | Reuters Novo Nordisk will start rolling out the first-ever GLP-1 pill for weight loss in the U.S. on Monday, the company announced, marking a new chapter of obesity […]
Read More
2026 will bring more GLP-1 weight loss pills — and new habits. These stocks are poised to benefit
The ripple is about to become a wave. Right now, there are numerous barriers for people who are considering treating their obesity with GLP-1 drugs. Early on, there were manufacturing bottlenecks that resulted in short supplies of Novo Nordisk ‘s Wegovy and Eli Lilly ‘s Zepbound. There were insurance coverage issues for these pricey treatments, […]
Read More
Novo Nordisk enters 2026 on the defense as it faces a ‘must-win’ battle in the U.S. market
Still life of the big three injectable prescription weight loss medicines. Ozempic, Victoza and Wegovy. (Photo by: Michael Siluk/UCG/Universal Images Group via Getty Images) Ucg | Universal Images Group | Getty Images Novo Nordisk’s shift from a market darling to a serious underperformer has set the stage for a transitional 2026 as the Danish drugmaker […]
Read More
Global stock markets’ winners and losers of 2025 — and where they’re headed
Global stocks have seen a stellar run in 2025, yet widening performance gaps and rising expectations suggest the new year may separate durable winners from fleeting momentum trades. The MSCI All Country World Index , which measures the performance of over 2,500 large and mid-cap equities from developed and emerging markets, has climbed over 21% […]
Read More